Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 1998

View Archived Issues

Company Profile: Mallinckrodt

Protein Design Labs: Q4 and FY 1997 highlights

Phase I trial results of DAB389IL-2 in lymphoma

Enrollment complete in phase II trials for rPAF-AH

Glaxo Wellcome enrolls patients in phase III flu drug trials

Pfizer will copromote Searle's COX-2 inhibitors in U.S.

Independent evaluation committee requests additional OxSODrol data

BioTransplant: Q4 and FY 1997 highlights

Warner-Lambert reveals new antipsychotic benzoxazinones

Oxcarbazepine derivatives with potent anticonvulsant activity

Neurocrine Biosciences describes compounds for increasing endogenous neuropeptide levels

Selective dopamine D3 ligands described by P&U

Allergan's new antiglaucoma agents

PKC inhibitors under study at Hoechst Marion Roussel

Advisory panel recommends approval of Synercid

New octreotide formulation launched in Italy

U.S. patent will issue covering Theratechnologies' AIDS gene therapy

Xenova, Lilly collaborate on new antithrombotics

Rebif launched in Canada: first drug to delay disease progression in remitting-relapsing MS

FDA accepts The Medicines Company's NDA for Hirulog

Beneficial effects of lisinopril on progression of retinopathy in IDDM

Role of nonsteroidal antiinflammatory therapy in asthma

Lisofylline enters pivotal testing for acute lung injury

Cheung describes results of preclinical evaluation of its BPH Rx system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...